

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/72834 A2

(51) International Patent Classification⁷: A61K 31/00

Nobuya [JP/JP]; 8-6-15, Hidaridai, Seika-cho, Soraku-gun, Kyoto 619-0237 (JP). SATOH, Masamichi [JP/JP]; 23-3, Shinogamo-yakochō, Sakyo-ku, Kyoto-shi, Kyoto 606-0837 (JP).

(21) International Application Number: PCT/JP00/03334

(22) International Filing Date: 24 May 2000 (24.05.2000)

(74) Agent: TAKASHIMA, Hajime; Yuki Bldg., 3-9, Hiranomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-0046 (JP).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (national): BR, CA, CN, JP, KR, US.

(30) Priority Data:
09/321,745 28 May 1999 (28.05.1999) US

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

Published:

— Without international search report and to be republished upon receipt of that report.

(72) Inventors; and

(75) Inventors/Applicants (for US only): MATSUOKA,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY

(57) Abstract: The present invention relates to an agent for the expression of long-term potentiation of synaptic transmission, which contains a compound having a brain somatostatin activation property as an active ingredient and to a screening method of an agent for the expression of long-term potentiation of synaptic transmission, which uses a somatostatin releasing property as an index. The present invention is useful for the prophylaxis and/or treatment of cerebral diseases of dementia, amnesia, manic-depressive psychosis, schizophrenia, Parkinson's disease, psychosomatic disease and the like.

WO 00/72834 A2